These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18449489)

  • 1. From pharmacogenomics to translational biomarkers.
    Mendrick DL
    Methods Mol Biol; 2008; 460():195-220. PubMed ID: 18449489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and genetic biomarkers of toxicity.
    Mendrick DL
    Toxicology; 2008 Mar; 245(3):175-81. PubMed ID: 18206287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety.
    Beitelshees AL; McLeod HL
    Trends Pharmacol Sci; 2006 Sep; 27(9):498-502. PubMed ID: 16876261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in aquatic plants: selection and utility.
    Brain RA; Cedergreen N
    Rev Environ Contam Toxicol; 2009; 198():49-109. PubMed ID: 19253039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational research in the pharmaceutical industry: from theory to reality.
    Sultana SR; Roblin D; O'Connell D
    Drug Discov Today; 2007 May; 12(9-10):419-25. PubMed ID: 17467579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics for brain disorders--the promise for biomarkers.
    Ward M; Güntert A; Campbell J; Pike I
    Ann N Y Acad Sci; 2009 Oct; 1180():68-74. PubMed ID: 19906262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the bench to the clinic and back again: translational biomarker discovery using in silico mining of pharmacogenomic data.
    Mendrick DL; Daniels KK
    Biomark Med; 2007 Aug; 1(2):319-33. PubMed ID: 20477406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in translation; past, present and future.
    Lock EA; Bonventre JV
    Toxicology; 2008 Mar; 245(3):163-6. PubMed ID: 18272278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current trends and strategic directions in the use of pharmacogenomics to identify translational biomarkers.
    Mendrick DL
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):37-42. PubMed ID: 17265739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective.
    Alvarez-Llamas G; de la Cuesta F; Barderas ME; Darde V; Padial LR; Vivanco F
    Expert Rev Proteomics; 2008 Oct; 5(5):679-91. PubMed ID: 18937558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating genomics, proteomics and bioinformatics in translational studies of molecular medicine.
    Ostrowski J; Wyrwicz LS
    Expert Rev Mol Diagn; 2009 Sep; 9(6):623-30. PubMed ID: 19732006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
    Karsdal MA; Henriksen K; Leeming DJ; Mitchell P; Duffin K; Barascuk N; Klickstein L; Aggarwal P; Nemirovskiy O; Byrjalsen I; Qvist P; Bay-Jensen AC; Dam EB; Madsen SH; Christiansen C
    Biomarkers; 2009 May; 14(3):181-202. PubMed ID: 19399662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
    Muller PY; Dieterle F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1023-38. PubMed ID: 19611406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease.
    Hurks R; Peeters W; Derksen WJ; Hellings WE; Hoefer IE; Moll FL; de Kleijn DP; Pasterkamp G
    Thromb Haemost; 2009 Jan; 101(1):48-54. PubMed ID: 19132188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of human populations for early markers of cadmium toxicity: a review.
    Fowler BA
    Toxicol Appl Pharmacol; 2009 Aug; 238(3):294-300. PubMed ID: 19433102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
    Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.